Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMY-920 in Relapsed or Refractory Myeloma
NCT05546723Phase 1Recruiting
- Sponsor
- Luminary Therapeutics
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAFF CAR-T in multiple myeloma (MM), sponsored by Luminary Therapeutics. Primary endpoints: Recommended Phase II Dose at 24 months and Maximum Tolerated Dose at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
BAFF CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05546723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546723.